Author

Catherine McNamara Page 2

Catherine McNamara, PharmD, BCPS, is a clinical pharmacogenomics specialist at an academic medical center in Boulder, Colorado. She directs a clinical testing service focused on gene-based dosing and investigates how variations in CYP enzymes affect drug response and patient toxicity. McNamara received her PhD in pharmaceutical sciences from the University of California, San Francisco, and she contributes to Biology Insights on medication science.

What Are CYP2D6 Inhibitors and How Do They Affect You?
The Dabigatran Reversal Agent and How It Works
What Is ASO Therapy and How Does It Work?
Oligonucleotide Therapeutics: A New Class of Drugs
Sotatercept’s Mechanism of Action in Pulmonary Hypertension
What Are siRNA Drugs and How Do They Work?
What Is an Efflux Ratio and How Does It Affect Medications?
What Is an Ampakine? Uses, Effects, and Potential Risks
Olpasiran: A Treatment for High Lipoprotein(a) Levels
Orexin Agonist: A New Class of Wakefulness Medication
What Are CYP450 Substrate Drugs & How Do They Work?
What Is the TPMT Enzyme and How Does It Affect Drugs?
CKD-510 for CMT: Mechanism, Trials, and Future Outlook
What Is Conolidine and How Does It Relieve Pain?
Hydroxyurea’s Mechanism of Action for Sickle Cell Disease
What Is a USP1 Inhibitor and How Does It Work?
Dalfampridine MOA: How It Works for Multiple Sclerosis
How Tacrolimus Metabolism Works in the Body
Concurrent Use of Fluconazole and Ibuprofen: Mechanisms and Clinical Implications
Renal Impairment: Pharmacokinetics and Dosage Adjustments
DNMT Inhibitors: Critical Advances for Disease Treatment
Levofloxacin: Pharmacokinetics, Stability, and Formulation Impact
Pharmacokinetics and Dosage in Hypoalbuminemia Treatment
Lisinopril for Black People: Key Mechanisms and Variation
Rapalink-1: Brain-Specific mTOR Inhibition Potential
Target Identification in Drug Discovery: Current Strategies